How is radioactive iodine (I-131) therapy administered for Graves disease, including preparation, dosing, safety precautions, and follow-up?

How to Administer Radioactive Iodine (I-131) Treatment for Graves Disease

Administer a single dose of 10-15 mCi of I-131 with the goal of rendering the patient hypothyroid, not euthyroid. This fixed-dose approach is simple, effective, and achieves cure rates of 69-75% at 6-12 months 1.

Pre-Treatment Preparation

Patient Selection and Contraindications

• Exclude pregnancy absolutely: Obtain a pregnancy test within 48 hours before treatment in all women of childbearing potential and verify negative results before administering I-131 1
• Contraindicate treatment in breastfeeding women 2
• Require at least 6 months of contraception after treatment for patients planning pregnancy 2
• Avoid in patients with urinary incontinence (contamination risk) 3

Medical Optimization Before Treatment

High-risk patients require pre-treatment stabilization - specifically those who are extremely symptomatic or have free T4 levels 2-3 times the upper limit of normal 1:

• Beta-blockers: Start in all elderly patients, those with heart rate >90 bpm, or cardiovascular disease 1

• Methimazole pre-treatment: Consider in high-risk patients (severe symptoms, very elevated T4, elderly, significant comorbidities including atrial fibrillation, heart failure, renal failure, poorly controlled diabetes) 1

  • If using methimazole: Stop 3-5 days before I-131, restart 3-7 days after, taper over 4-6 weeks 1
  • Caution: Methimazole may reduce I-131 efficacy 1

• Optimize all comorbid conditions (cardiovascular disease, diabetes, infections) before administering I-131 1

Dosing Strategy

Fixed Dose Approach (Recommended for Simplicity)

Administer 10-15 mCi as a single dose 1:

• 10 mCi achieves hypothyroidism in 69% at 1 year 1
• 15 mCi achieves hypothyroidism in 75% at 6 months 1
• This approach is equally effective as calculated dosing 1

Calculated Dose Approach (Alternative)

If you prefer calculated dosing, use: Activity (mCi) = gland weight (g) × 0.15 mCi/g ÷ (24-hour uptake as decimal) 1

• Requires thyroid size estimation (palpation or ultrasound) and 24-hour radioiodine uptake
• Aim for ≥150 μCi/g (≥0.15 mCi/g) of thyroid tissue to ensure adequate treatment 1
• Higher doses (200-300 μCi/g) may be needed for large glands (50-80 g) 1

Important: The goal is hypothyroidism, not euthyroidism - this maximizes cure rates and minimizes cancer risk from residual irradiated tissue 1.

Safety Precautions and Patient Instructions

Radiation Safety

Provide written and oral instructions on radiation precautions 3, 1:

• Distance restrictions vary by age of contacts:
  • Avoid close contact with pregnant women, infants <1 month, and children <10 years (most radiation-sensitive) 3
  • Limit contact duration based on dose administered (consult nuclear medicine guidelines) 3
  • Over-60 year-olds have lower cancer risk and can tolerate higher exposure 3

Minimize Non-Thyroid Irradiation

• Hydration: Instruct adequate fluid intake to reduce exposure to stomach, intestines, salivary glands, lacrimal glands, and bladder 3
• These organs receive the highest non-thyroid radiation exposure 3

Post-Treatment Follow-Up

Early Monitoring (Critical to Prevent Complications)

Check TSH AND free T4 at 4 weeks, then every 4-6 weeks for 6 months 3, 1:

• TSH alone is insufficient early on (may remain suppressed 4-6 weeks despite falling T4) 3
• Early hypothyroidism occurs in a significant number within the first month 3
• Untreated hypothyroidism can worsen or trigger Graves' ophthalmopathy 3

Within First 1-2 Months

Assess free T4 and total T3; if still thyrotoxic, continue monitoring every 4-6 weeks 1

Treatment Failure

Consider retreatment if:

• Hyperthyroidism persists at 6 months, OR
• Minimal response at 3 months 1

Failure is more common with:

• Young age, male gender
• Large thyroid (>60 g)
• Poor iodine retention
• Recent antithyroid medication use 3

Common Pitfalls to Avoid

1. Underdosing: Using <150 μCi/g leads to higher failure rates and potential cancer risk in residual tissue 1

2. Forgetting pregnancy testing: Always verify within 48 hours of treatment 1

3. Inadequate pre-treatment stabilization: High-risk patients (severe hyperthyroidism, elderly, cardiac disease) need beta-blockers and possibly methimazole first 1

4. Delayed hypothyroidism detection: Early hypothyroidism is common and requires TSH + free T4 monitoring, not TSH alone 3

5. Continuing methimazole too close to treatment: Stop 3-5 days before I-131 to avoid reducing efficacy 1

6. Inadequate radiation safety counseling: If patients cannot follow precautions, choose alternative therapy 1

Long-Term Outcomes

• Most patients (75-88%) achieve cure after 1-2 doses 4
• Hypothyroidism is the expected outcome and occurs in most patients by 3 months with ablative doses 3
• Long-term euthyroidism maintained in approximately 50% at 10 years and 33% at 25 years with calculated dosing aimed at euthyroidism 4
• No increased risk of cancer, leukemia, or cardiovascular mortality with proper treatment 3, 5